Cor Vasa 2025, 67(Suppl.2):7-13 | DOI: 10.33678/cor.2024.106

(Current view on beta-blockers in the therapy of heart failure)

Filip Málek
Kardiologická klinika,1. lékařská fakulta Univerzity Karlovy a Nemocnice Na Homolce, Praha, Česká republika

Beta-blockers are drugs demonstrably modifying course of heart failure with reduced ejection fraction. Beta-blockers reduce all cause mortality, risk of sudden death and risk of death due to worsening of heart failure. They reduce cardiovascular mortality and risk of hospitalizations; they influence morbidity of the patients positively. The treatment is usually well tolerated. It is necessary to reach maximal tolerated drug dose, the effect is dose-dependent. Beta-blockers rightfully belong to the group of fundamental drugs for the treatment of heart failure.

Keywords: Beta-blockers, Bisoprolol, Carvedilol, Heart failure, Metoprolol, Nebivolol

Received: December 21, 2024; Revised: December 21, 2024; Accepted: December 23, 2024; Prepublished online: June 2, 2012; Published: April 15, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. (Current view on beta-blockers in the therapy of heart failure). Cor Vasa. 2025;67(Suppl.2):7-13. doi: 10.33678/cor.2024.106.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726. Go to original source... Go to PubMed...
    2. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999,353:9-13. Go to original source...
    3. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in-congestive heart failure (MERIT-HF). Lancet 1999,353: 2001-2007. Go to original source...
    4. Packer M, Fowler MB, Roecker EB, et al. Effect of Carvedilol on the Morbidity of Patients with Severe Chronic Heart Failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation 2002,106:2194-2199. Go to original source... Go to PubMed...
    5. Flather MD, Shibata MC, Coats AJ, et al., SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005,26:215-225. Go to original source... Go to PubMed...
    6. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895-e1032. Go to original source... Go to PubMed...
    7. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers in Heart Failure Collaborative Group. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double blind randomized trials. Eur Heart J 2018;39:2635. Go to original source... Go to PubMed...
    8. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001;357:1385-1390. Go to original source... Go to PubMed...
    9. Waagstein F, Hjakmarson A, Varnauskas E, et al. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1036. Go to original source... Go to PubMed...
    10. Swedberg K. History of β blockers in congestive heart failure. Heart 1998;79(Suppl 2):S29-S30. Go to original source... Go to PubMed...
    11. Swedberg K, Hjalmarson A, Waagstein F, et al. Benefical effects of long-term β blockade in congestive heart failure. Br Heart J 1980;44:117-133. Go to original source... Go to PubMed...
    12. Swedberg K, Hjalmarson A, Waagstein F, et al. Prolongation of survival in congestive cardiomyopathy by betareceptor blockade. Lancet 1979;1:1374-1376. Go to original source... Go to PubMed...
    13. Bristow MR, Minobe W, Raynolds MV, et al. Reduce β1 receptor mRNA abundance in the failing human heart. J Clin Invest 1993,92:2737-2745. Go to original source... Go to PubMed...
    14. Waagstein F, Bristow MR, Swedberg K, et al. Benefical effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993;342:1441-1446. Go to original source... Go to PubMed...
    15. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;2:823-827. Go to original source... Go to PubMed...
    16. Norwegian Multicenter Study Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807. Go to original source... Go to PubMed...
    17. Hawkins CM, Richardson DW, Vokonas PS. Effect of propranolol in reducing mortality in older myocardial infarction patients. The Beta-Blocker Heart Attack Trial experience. Circulation 1983;67:194-197.
    18. Olsson G, Rehnqvist N, Sjogren A, et al. Long-term treatment with metoprolol after myocardial infarction: effect on 3 year mortality and morbidity. J Am Coll Cardiol 1985;5:1428-1437. Go to original source... Go to PubMed...
    19. Bangalore S, Makani H, Radford M, et al. Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials. Am J Med 2014;127:939-953. Go to original source... Go to PubMed...
    20. Maroko PR, Kjekshus JK, Sobel BE, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971;43:67-82. Go to original source... Go to PubMed...
    21. Reimer KA, Rasmussen MM, Jennings RB. Reduction by propranolol of myocardial necrosis following temporary coronary artery occlusion in dogs. Circ Res 1973;33:353-363. Go to original source... Go to PubMed...
    22. Kjekshus JK. Importance of heart rate in determining beta- -blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-49F. Go to original source... Go to PubMed...
    23. Lange R, Kloner RA, Braunwald E. First ultra-short-acting betaadrenergic blocking agent: its effect on size and segmental wall dynamics of reperfused myocardial infarcts in dogs. Am J Cardiol 1983;51:1759-1767. Go to original source... Go to PubMed...
    24. Mueller HS, Ayres SM. Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man. J Clin Invest 1980;65:338-346. Go to original source... Go to PubMed...
    25. Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371. Go to original source... Go to PubMed...
    26. Hjalmarson A, Herlitz J. Limitation of infarct size by beta blockers and its potential role for prognosis. Circulation 1983;67(6 Pt 2):168-171.
    27. Waldenstrom AP, Hjalmarson AC. Factors modifying ischemic injury in the isolated rat heart. Acta Med Scand 1977;201: 533-538. Go to original source... Go to PubMed...
    28. Freemantle N, Cleland J, Young P, et al. Beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730-1737. Go to original source... Go to PubMed...
    29. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998;339:489-497. Go to original source... Go to PubMed...
    30. Lopez-Sendón J, Swedberg K, McMurray J, et al. Expert consensus document on β-adrenergic receptor blockers. The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004;25:1341-1362. Go to original source... Go to PubMed...
    31. Tamargo JL, Delpón E. Optimisation of b-blockers pharmacology. J Cardiovasc Pharmacol 1990;16(Suppl. 5):S8-S10. Go to original source...
    32. Frishman WH, Lazar EJ, Gorodokin G. Pharmacokinetic optimisation of therapy with beta-adrenergic-blocking agents. Clin Pharmacokinet 1991;20:311-318. Go to original source... Go to PubMed...
    33. Frishman WH. Carvedilol. N Engl J Med 1998;339:1759-1765. Go to original source... Go to PubMed...
    34. Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res 1998;38:419-431. Go to original source... Go to PubMed...
    35. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). Circulation 1994;90:1765-1773. Go to original source... Go to PubMed...
    36. Van Veldhuisen DJ, Aass H, Allaf DE, et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur J Heart Fail 2006;8:539-546. Go to original source... Go to PubMed...
    37. Wikstrand J, Hjalmarson A, Waagstein F, et al. Dose of Metoprolol CR/XL and Clinical Outcomes in Patients With Heart Failure. J Am Coll Cardiol 2002;40:491-498. Go to original source... Go to PubMed...
    38. Goldstein S, Fagerberg B, Hjalmarson A, et al. Metoprolol Controlled Release/Extended Release in Patients With Severe Heart Failure. J Am Coll Cardiol 2001;38:932-938. Go to original source... Go to PubMed...
    39. Poole-Wilson PA, Swedberg K, Cleland JFG, et al., for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003;362:7-13. Go to original source... Go to PubMed...
    40. Wikstrand J, Wedel H, Castagno D, McMurray JJV. The large- -scale placebo-controlled beta-blocker studies in systolic heart failure revisited: results from CIBIS -II, COPERNICUS and SENIORS-SHF compared with stratified subsets from MERIT-HF. J Int Medicine 2014;275:134-143. Go to original source... Go to PubMed...
    41. Bristow MR. Pathophysiologic and pharmacologic rationale for clinical management of chronic hart failure with beta-blocking agents. Am J Cardiol 1993;71:12C-22C. Go to original source... Go to PubMed...
    42. Bouzamondo A, Hulot JS, Sanchez P et al. Beta-blocker treatment in heart failure. Fundam Clin Pharmacol 2001;15: 95-109. Go to original source... Go to PubMed...
    43. Waagstein F. Beta-blockers in congestive heart failure: the evolution of a new treatment concept - mechanism of action and clinical implications. J Clin Basic Cardiol 2002;5:215-223.
    44. Lábr K, Špinar J, Pařenica J, et al. Betablokátory v registru chronického srdečního selhání FAR NHL. Kardiol Rev Int Med 2017;19:68-72.
    45. Špinarová M, Špinar J, Pařenica J, et al. Preskripce a dávkování inhibitorů RAAS u pacientů s chronickým srdečním selháním v registru FAR NHL. Vnitř Lék 2018;64:13-18. Go to original source...
    46. Málek F. Reaching betablockers target dose in elderly patients with chronic heart failure. Cor Vasa 2014;56:e37-e41. Go to original source...
    47. Düngen HD, Apostolović S, Inkrot S, et al.; on behalf of CIBIS- -ELD Investigators. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail 2011;13:670-680. Go to original source... Go to PubMed...
    48. Marti CN, Fonarrow GC, Anker SD, et al. Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. Eur J Heart Fail 2019;21:286-296. Go to original source... Go to PubMed...
    49. Yancy CW, Januzzi JL Jr, Allen LA, et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology task force on expert consensus decision pathways. J Am Coll Cardiol 2018;71:201-230. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes